Binding molecule specific for CD39 and use thereof
US12391756B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 4, 2020 |
| Grant date | Aug 19, 2025 |
| Priority date | — |
| Expiry date | Nov 25, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/90
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a binding molecule specifically for CD39 and the use thereof. Specifically, provided is an antibody that binds to CD39 and inhibits the activity of CD39 or an antigen binding part thereof, the use of the antibody or the antigen binding part thereof in the treatment of diseases, a nucleic acid molecule encoding the antibody or the antigen binding part thereof, an expression vector for expressing the antibody or the antigen binding part thereof, a host cell, and a preparation method.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.